MKMarian Klinger

Marian Klinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marian Klinger has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multisystem Amyloidosis in a Coal Miner with Silicosis: Is Exposure to Silica Dust a Cause of Amyloid Deposition?

    by Tomasz Gołębiowski, Jakub Kuźniar, Tomasz Porażko, Renata Wojtala, Andrzej Konieczny, Magdalena Krajewska, Marian Klinger

    The over-secretion of monoclonal immunoglobulin light chains by clonal B cells followed by the aggregation and extracellular deposition of fibrillar deposits are responsible forthe clinical course AL amyloidosis. It is well documented that silica significantly increases the number of immunoglobulin-secreting cells. In the present paper, we report on a coal miner with silicosis and fast progressing primary amyloidosis with predominantly heart, kidney, and lung manifestations. Severeheart failure due to myocardial hypertrophy resulted in the patient’s death. We conclude that long-term environmental silica exposure and silica deposition may contribute to the development of monoclonal gammopathy and amyloidosis due to chronic stimulus and the dysregulation of the immune system.


    • 1 June 2011
      • Vol. 30  (180) , 427-9

    [The immunoglobulin replacement therapy in adult patients with renal diseases].

    by Marian Klinger

    The review discusses the immunoglobulin replacement therapy in patients with renal involvement in the course of common variable immunodeficiency and in the dialysed patients with multiple myeloma. The effects of high, anti inflammatory immunoglobulin doses in systemic vasculitis and in systemic lupus erythematosus are presented. The data on the intravenous immunoglobulins use in primary membranous nephropathy are also given.

  • The Effect of Type and Vascular Access Quality on the Outcome of Chronic Hemodialysis Treatment

    by Krzysztof Letachowicz, Wacław Weyde, Waldemar Letachowicz, Marian Klinger


  • The Role of Heparanase in Diseases of the Glomeruli

    by Maciej Szymczak, Jakub Kuźniar, Marian Klinger

    The glomerular basement membrane (GBM) is a kind of net that remains in a state of dynamic equilibrium. Heparan sulfate proteoglycans (HSPGs) are among its most important components. There are much data indicating the significance of these proteoglycans in protecting proteins such as albumins from penetrating to the urine, although some new data indicate that loss of proteoglycans does not always lead to proteinuria. Heparanase is an enzyme which cleaves β 1,4 d-glucuronic bonds in sugar groups of HSPGs. Thus it is supposed that heparanase may have an important role in the pathogenesis of proteinuria. Increased heparanase expression and activity in the course of many glomerular diseases was observed. The most widely documented is the significance of heparanase in the pathogenesis of diabetic nephropathy. Moreover, heparanase acts as a signaling molecule and may influence the concentrations of active growth factors in the GBM. It is being investigated whether heparanase inhibition may cause decreased proteinuria. The heparanase inhibitor PI-88 (phosphomannopentaose sulfate) was effective as an antiproteinuric drug in an experimental model of membranous nephropathy. Nevertheless, this drug is burdened by some toxicity, so further investigations should be considered.


  • Evolution of Bone Disease at 2 Years After Transplantation: A Single-Center Study

    by K. Falkiewicz, M. Boratyńska, S.C. Zmonarski, A. Milewicz, D. Patrzałek, P. Biecek, M. Klinger


  • Primary idiopathic glomerulonephritis: modern algorithm for diagnosis and treatment

    by Marian Klinger, Oktawia Mazanowska

    In most countries glomerulonephritis is the second most common cause of the end-stage renal disease, after diabetic nephropathy in renal replacement therapy programs. Occurence of primary glomerular diseases in young and middle aged patients, in whom they restrain their lives and professional careers, results in their particular position among causes of replacement therapy. A highly important component of the therapeutic approach to nephrotic patients is appropriate symptomatic treatment. Proteinuria reduction is crucial in the prevention of progressive kidney function decline in the course of glomerulonephritis. A long-term therapy of glomerulonephritis should be conducted both by the general internal medicine specialist and the nephrologist. The treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers can be performed by the internist, but the immunosuppressive programs should be initiated and supervised by the nephrologist.

  • Radial Artery–Perforating Vein Fistula for Hemodialysis

    by Waclaw Weyde, Mariusz Kusztal, Magdalena Krajewska, Waldemar Letachowicz, Ewa Watorek, Tomasz Porazko, Miroslaw Banasik, Dariusz Janczak, Jerzy Garcarek, Katarzyna Madziarska, et al.


  • Modern nephrology – new methods, new treatments and still numerous difficult challenges

    by Marian Klinger

    DOI: 10.20452/pamw.93, Published online: March 01, 2007, Authors: Marian Klinger

  • Obesity is not an obstacle for successful autogenous arteriovenous fistula creation in haemodialysis

    by W. Weyde, M. Krajewska, W. Letachowicz, T. Porazko, E. Watorek, M. Kusztal, M. Banasik, T. Golebiowski, H. Bartosik, K. Madziarska, et al.

    Obesity, which is often associated with diabetes, is increasingly encountered in the haemodialysed population, and this may produce difficulty in autogenous arteriovenous fistula creation. Prosthetic angioaccess or catheters, when used in place of autogenous fistulas, increase thrombotic and infectious complications in these already challenged patients. This prospective study was undertaken to assess the feasibility of autogenous arteriovenous fistula creation in 71 obese patients (BMI 34.6 +/- 7.8). We performed a two-stage procedure, in which radio-cephalic fistula formation was followed by subcutaneous transposition of the venous component for safe and easy puncture. Fistulas suitable for puncture, having blood flows of 799 +/- 285 ml/min, and sufficient to perform adequate haemodialysis (Kt/V 1.24) were achieved in 85% of the patients. Primary patency rates were 65% and 59% at 6 and 12 months, respectively, and secondary patency rates were 83% both at 6 and 12 months. Obesity does not prevent successful autogenous arteriovenous fistula formation, and may protect forearm venous vessels from the iatrogenic damage that occurs before the onset of haemodialysis therapy.


    • 1 August 2006
      • Vol. 21  (122) , 148

    [Gene expression of INF-gamma, IL-10, IL-2, IL-6, PDGF-B i TGF-beta in kidney tissue after renal transplantation].

    by Dorota Kamińrska, B Tyran, O Mazanowska, Jerzy Rabczyński, Dariusz Patrzałek, Piotr Szyber, Paweł Chudoba, Marian Klinger

    The aim of the study was to evaluate the effect of brain death, ischemia-reperfusion injury and alloreactivity of some cytokines on intragraft mRNA expression. We have examined 49 needle core biopsies of kidney allografts from cadaveric donors. Samples were taken before harvesting, after cold ischemia and approximately after 20-30 minutes of reperfusion. We have also assessed 56 allograft biopsies taken after transplantation. Tubular and glomerular expression of IL-2, IL-6, IL-10, IFN-gamma, TGF-beta 1 and PDGF-B mRNA was assessed using semiquantitative evaluation of the RT-PCR in situ on paraffin tissue sections. In all pre-procurement specimens high glomerular and tubular IL-2, IL-6, IL-10, TGF-beta 1, PDGF-B and IFN-gamma mRNA expression was detected. After reperfusion an increase of IL-2, IL-6, and IL-10 mRNA expression was observed in all specimens and was limited only to tubules. Biopsies samples with borderline changes exhibited the lowest levels of cytokine gene expression close to the intensity in control specimens. An intense, comparing to normal kidney, tubular and glomerular all examined cytokines gene expression was also noticed during acute rejection. No significant differences between acute cellular and vascular rejection were noticed. The mRNA expression of IFN-gamma and IL-2, IL-6, IL-10 in chronic rejection did not differ from acute rejection. The tubular expressions of mRNA for IL-6 and TGF-gamma 1 in biopsies with acute rejection obtained from patients treated with MMF were significantly lower than in biopsies obtained from patients treated with azathioprine.